search
Back to results

Mechanisms for Dyspnea on Exertion in Children With Obesity and Asthma: Distinct Physiological Phenotypes

Primary Purpose

Asthma in Children, Dyspnea; Asthmatic, Obesity, Childhood

Status
Not yet recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Control
Albuterol
Sponsored by
Ohio State University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Asthma in Children focused on measuring Pediatric, Breathlessness, Ventilatory Constraints, Exercise

Eligibility Criteria

9 Years - 17 Years (Child)All SexesDoes not accept healthy volunteers

General inclusion criteria:

  • Age range: 9-17 years of age
  • Participants with physician diagnosed asthma and on regular asthma controller therapy for at least 8 weeks prior to enrollment will be recruited for this study.

    • Objectively Confirmed Asthma Diagnosis: Asthma diagnosis will be confirmed objectively using spirometry (FEV1 < 80% predicted or FEV1/FVC < lower limit of normal), bronchodilator reversibility testing (post-bronchodilator improvement of ≥ 12% and 200mL in FEV1 or FVC; or a decrease in lung hyperinflation of at least 150 mL; ATS guidelines on lung function test interpretation), or a methacholine challenge test. Patients in whom asthma cannot be confirmed objectively will be excluded from the study.
  • Experience dyspnea on exertion as assessed by answering "yes" to one of the following two questions on the screening questionnaire: 1) Do you get short of breath with exertion? 2) Do you feel that your asthma is limiting you from participating in exercise?
  • Ability to communicate in English

Body mass index criteria (BMI): We will study two discrete groups of asthmatic children based on their BMI percentile:

  • Nonobese: BMI 5th-84th percentile based on norms from the Centers for Disease Control (CDC)
  • Obese: BMI ≥95th percentile and less than 170% of the 95th BMI percentile based on norms from the CDC

Exclusion criteria:

Criteria for pulmonary function: We will exclude asthmatic children with:

  • Severe asthma: Forced expiratory volume in 1s (FEV1) < 50% predicted
  • Restrictive pulmonary disease: Forced vital capacity (FVC) and total lung capacity (TLC) < 80% predicted
  • Diffusion limitation: Diffusing capacity relative to alveolar volume (DLCO/VA) < 80% predicted

Daily activity levels: Children participating in regular vigorous conditioning exercise such as running, jogging, aerobics, cycling, or swimming for ≥60min/session and ≥five times per week will be excluded to ensure similarity in physical activity levels between subjects and to avoid enrolling a potential high-fit, extremely active child. Children who participate in daily, unorganized physical activity (i.e., majority of children), will not be excluded. Children who are sedentary or only participate in school physical education classes will not be excluded.

The following exclusion criteria will be used in this study:

  • History of oral steroid medications for 4 weeks prior to enrollment
  • History of being admitted to an intensive care unit or being intubated because of their asthma in the past five years
  • History of allergy or hypersensitivity to albuterol or ipratropium or history of narrow-angle glaucoma that could get worse with ipratropium
  • History of vocal cord dysfunction
  • History of obesity hypoventilation syndrome
  • History of untreated sleep apnea
  • History of heart disease, metabolic disease, or renal disease that, in the opinion of the PI (or co-I's), would increase the risks of exercise testing or alter the physiological responses to exercise
  • History of significant mental illness that in the opinion of the PI (or co-I's) would interfere with study participation or increase risks to the participant
  • History of musculoskeletal abnormality that would preclude cycling exercise
  • Pregnant or become pregnant during their participation in the study
  • History of other significant illnesses that, in the opinion of the PI (or co-I's), either increase risks of participation or alter the physiological responses to exercise
  • Inability to successfully complete pulmonary function or exercise testing measurements or difficulty with following instructions during testing
  • Inability to tolerate testing procedures or complications related to testing
  • If a participant develops hypoxemia or meets indications for terminating exercise, the exercise test will be terminated, and the participant will be referred for further evaluation In general, all participants will be encouraged to follow up with their asthma care provider or pediatrician for any health concerns that are discovered during their participation.

Sites / Locations

  • The Ohio State University

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Exercise test

Arm Description

All participants will undergo a moderate-intensity exercise test under three conditions in a repeated measures study design: Control Albuterol

Outcomes

Primary Outcome Measures

Expiratory flow limitation
Units: % of tidal volume, measured as overlap between exercise tidal flow volume loop and maximal expiratory flow volume loop
Dynamic hyperinflation
Units: % of total lung capacity, measured as change in end-expiratory lung volume from rest to exercise
Forced expiratory volume in 1 s
Units: Litres, measured with spirometry
Peripheral airway reactivity (R5-R20)
Units: % change from pre to post exercise, measured with impulse oscillometry

Secondary Outcome Measures

Rating of perceived breathlessness
Borg 0 - 10 scale

Full Information

First Posted
November 29, 2019
Last Updated
October 23, 2023
Sponsor
Ohio State University
Collaborators
Nationwide Children's Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04184609
Brief Title
Mechanisms for Dyspnea on Exertion in Children With Obesity and Asthma: Distinct Physiological Phenotypes
Official Title
Mechanisms for Dyspnea on Exertion in Children With Obesity and Asthma: Distinct Physiological Phenotypes
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
April 1, 2024 (Anticipated)
Primary Completion Date
November 30, 2027 (Anticipated)
Study Completion Date
November 30, 2028 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ohio State University
Collaborators
Nationwide Children's Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The overall objective of this study is to better understand the respiratory mechanisms provoking dyspnea on exertion in obese asthmatic children.
Detailed Description
Obesity and asthma are the most common diseases of childhood, causing activity limitation and impaired quality of life. Most obese asthmatic children report dyspnea on exertion (DOE) as their primary asthma symptom. Fear of dyspnea promotes sedentariness and reduces exercise capacity and quality of life. DOE in asthmatic children is typically attributed to bronchoconstriction but it is also possible that obesity is an equal or even major contributor to dyspnea. Excess chest and abdominal weight in obese children results in low lung volumes, which increases the risk of mechanical ventilatory constraints such as expiratory flow limitation, dynamic hyperinflation, and airway closure, all of which can provoke DOE. Unnecessary use of corticosteroids and other asthmatic medication in obese asthmatic children cannot treat obesity-specific mechanical ventilatory constraints and could have unintended deleterious effects. Therefore, there is an urgent need to better understand the mechanisms involved in DOE to provide evidence-based symptom management for obese asthmatic children that will promote regular physical activity and lessen DOE. The overall objective of this study is to better understand the respiratory mechanisms provoking DOE in obese asthmatic children. The investigators hypothesize that low lung volume breathing in obesity leads to mechanical ventilatory constraints in the presence or absence of bronchoconstriction during exercise. Whereas DOE attributable to bronchoconstriction should respond to bronchodilators, DOE attributable to obesity-specific mechanical ventilatory constraints will not respond to bronchodilators. A comprehensive physiological pulmonary function and exercise-testing based approach will be used to identify 9-17-year-old obese asthmatic children who do and do not bronchoconstrict during exercise. The presence/absence of bronchoconstriction will be determined by a comprehensive measure of exercise-induced central and peripheral airway reactivity using spirometry and impulse oscillometry (i.e., greater than or equal to 10% reduction in forced expiratory volume in 1s, FEV1, or greater than or equal to 40% increase in peripheral airway resistance, R5-20, will be indicative of bronchoconstriction). The investigators will also determine the mechanisms by which bronchodilators like albuterol affect bronchoconstriction amd mechanical ventilatory constraints in asthmatic children with obesity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma in Children, Dyspnea; Asthmatic, Obesity, Childhood
Keywords
Pediatric, Breathlessness, Ventilatory Constraints, Exercise

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Model Description
2 repeated measures (within factor): Control and Albuterol
Masking
None (Open Label)
Allocation
N/A
Enrollment
48 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Exercise test
Arm Type
Experimental
Arm Description
All participants will undergo a moderate-intensity exercise test under three conditions in a repeated measures study design: Control Albuterol
Intervention Type
Other
Intervention Name(s)
Control
Other Intervention Name(s)
No-treatment
Intervention Description
In this condition, the participants will not receive any medications or drugs before exercise
Intervention Type
Drug
Intervention Name(s)
Albuterol
Other Intervention Name(s)
Ventolin
Intervention Description
180 mcg of Albuterol will be administered before exercise
Primary Outcome Measure Information:
Title
Expiratory flow limitation
Description
Units: % of tidal volume, measured as overlap between exercise tidal flow volume loop and maximal expiratory flow volume loop
Time Frame
up to 2 hours during the intervention (exercise)
Title
Dynamic hyperinflation
Description
Units: % of total lung capacity, measured as change in end-expiratory lung volume from rest to exercise
Time Frame
up to 2 hours during the intervention (exercise)
Title
Forced expiratory volume in 1 s
Description
Units: Litres, measured with spirometry
Time Frame
Pre to 30 min post exercise
Title
Peripheral airway reactivity (R5-R20)
Description
Units: % change from pre to post exercise, measured with impulse oscillometry
Time Frame
Pre to 30 min post exercise
Secondary Outcome Measure Information:
Title
Rating of perceived breathlessness
Description
Borg 0 - 10 scale
Time Frame
up to 2 hours during the intervention (exercise)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
9 Years
Maximum Age & Unit of Time
17 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
General inclusion criteria: Age range: 9-17 years of age Participants with physician diagnosed asthma will be recruited for this study. Objectively Confirmed Asthma Diagnosis: Asthma diagnosis will be confirmed objectively using spirometry (FEV1 < 80% predicted or FEV1/FVC < lower limit of normal), bronchodilator reversibility testing (post-bronchodilator improvement of ≥ 12% and 200mL in FEV1 or FVC; or a decrease in lung hyperinflation of at least 150 mL; ATS guidelines on lung function test interpretation). Patients in whom asthma cannot be confirmed objectively will be excluded from the study. Experience dyspnea on exertion as assessed by answering "yes" to one of the following two questions on the screening questionnaire: 1) Do you get short of breath with exertion? 2) Do you feel that your asthma is limiting you from participating in exercise? Ability to communicate in English Body mass index criteria (BMI): We will study asthmatic children with obesity based on their BMI percentile: • Obese: BMI ≥95th percentile and less than 170% of the 95th BMI percentile based on norms from the CDC Exclusion criteria: Criteria for pulmonary function: We will exclude asthmatic children with: Severe asthma: Forced expiratory volume in 1s (FEV1) < 50% predicted Restrictive pulmonary disease: Forced vital capacity (FVC) and total lung capacity (TLC) < 80% predicted Diffusion limitation: Diffusing capacity relative to alveolar volume (DLCO/VA) < 80% predicted Daily activity levels: Children participating in regular vigorous conditioning exercise such as running, jogging, aerobics, cycling, or swimming for ≥60min/session and ≥five times per week will be excluded to ensure similarity in physical activity levels between subjects and to avoid enrolling a potential high-fit, extremely active child. Children who participate in daily, unorganized physical activity (i.e., majority of children), will not be excluded. Children who are sedentary or only participate in school physical education classes will not be excluded. The following exclusion criteria will be used in this study: History of oral steroid medications for 4 weeks prior to enrollment History of being admitted to an intensive care unit or being intubated because of their asthma in the past five years History of allergy or hypersensitivity to albuterol On long acting muscarinic antagonists (LAMA) History of vocal cord dysfunction History of obesity hypoventilation syndrome History of untreated sleep apnea History of heart disease, metabolic disease, or renal disease that, in the opinion of the PI (or co-I's), would increase the risks of exercise testing or alter the physiological responses to exercise History of significant mental illness that in the opinion of the PI (or co-I's) would interfere with study participation or increase risks to the participant History of musculoskeletal abnormality that would preclude cycling exercise Pregnant or become pregnant during their participation in the study History of other significant illnesses that, in the opinion of the PI (or co-I's), either increase risks of participation or alter the physiological responses to exercise Inability to successfully complete pulmonary function or exercise testing measurements or difficulty with following instructions during testing Inability to tolerate testing procedures or complications related to testing If a participant develops hypoxemia or meets indications for terminating exercise, the exercise test will be terminated, and the participant will be referred for further evaluation In general, all participants will be encouraged to follow up with their asthma care provider or pediatrician for any health concerns that are discovered during their participation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dharini Bhammar, MBBS, PhD
Phone
2147709382
Email
bhammar.1@osu.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dharini M Bhammar, MBBS, PhD
Organizational Affiliation
Ohio State University
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Ohio State University
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dharini M Bhammar, PhD
Phone
214-770-9382
Email
bhammar.1@osu.edu
First Name & Middle Initial & Last Name & Degree
Dharini M Bhammar, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There is no plan to share all of the individual participant data collected during the trial.

Learn more about this trial

Mechanisms for Dyspnea on Exertion in Children With Obesity and Asthma: Distinct Physiological Phenotypes

We'll reach out to this number within 24 hrs